Company News
Akari Therapeutics Shares Jump 50% on KRAS Data
Akari Therapeutics shares surged ~50% in after‑hours trading on 22 May 2026 after releasing preclinical KRAS‑combination data.
The study showed AKTX‑101 ADC with KRAS inhibitor adagrasib produced syne
